Asundexian
Transient Ischemic Attack
BayerSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Transient Ischemic Attack cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin Sichuan Provincial People's Hospital | Phase 4 | BBB |
Clopidogrel Sichuan Provincial People's Hospital | Phase 4 | BBB |
Ticagrelor Mazandaran University of Medical Sciences | Phase 3 | BBB |
Cilostazol Stanford University | Phase 4 | BBB |
Rivaroxaban General Hospital of Shenyang Military Region | Phase 4 | BBB |
View all 42 →
Same molecule, other indications
Asundexian is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →